Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Keep them coming!
AMBS
It seems like your efforts and claims have fallen on def ears. Perhaps this is not the right place to address it, but with the SEC itself.
I'm looking forward to the next video.
NTEK Long
Well, it took SEC about 8 months to bust a few PnD promoters, one of which promoted this very same stock a while ago.
There you go. 0.16's are gone!
0.16 will soon be history. T-1 week.
AMBS
Nuvola being in Google's supported device list is a huge statement as to where the company is heading.
The market will react in due time.
NTEK
NP-1 listed in Google Play as a Supported Device!!!
I hope you're in mate! The party just started.
LOL, Indeed. It's tea time!
J&J owns it, but don't forget that these subsidiaries had acquired other companies and had absorbed them; what I mean is that Amarantus could become Jannsen, and of course, it'll be under the J&J umbrella.
My hunch is it'll be Janssen Pharmaceuticals; not only because AMBS was selected to move into their QB3 labs last year, but also given that Janssen announced early this year that it would be targeting unmet global health needs:
Janssen Announces New Group Targeting Unmet Global Health Needs
The NP-1 is spreading like a virus and reaching different markets. Awesome!
Another shareholder receiving his NP-1. Keep them coming.
Thanks for sharing GL81!
NTEK!
Thank you for sharing it Magic. Enjoy!
Excellent! We're on track for a great achievement.
Yes, Interferon; I'm glad you noticed it. I specifically brought up this protein (through Pegasys) for a reason I wanted to share, but decided I rather not.
Excellent, great pics! Enjoy!
It could take less than 3 years. Here is an example:
Pegasys, used for the treatment of Hepatitis C, was submitted by Roche in May 2000 and was approved in October 2002. Only 29 months.
It definitely could take longer, but I rather be in the optimistic side.
It could even exceed $10 bil annually; here is an example:
Great! More are on the way.
I'm here for both the long term (I'm aware of the implications from your first two sentences) and for the short term; his blog moved the stock indeed. The way I see it, we'll capitalize in either case.
3Q is knocking on the door!
GLTU
They should be in if they know where AMBS is heading.
GLTU
I've been here since fall 2012 and I don't recall hearing anything similar.
$AMBS
Looking back on the last two years, it is amazing to see how the MANF story has unfolded in conjunction with the other corporate initiatives the Company has undertaken including the addition of LymPro and Eltoprazine to our pipeline. The effort to diversify our pipeline was largely initiated to allow the Company’s scientific team to uncover MANF’s true value by identifying market opportunities with the highest net present value, which in biotechnology generally means fastest path to market in an orphan indication. That strategy bore fruit in the middle of 2013, when the Company identified in scientific literature a reference to MANF’s utility in Retinitis Pigmentosa (RP) from the University of Miami’s Bascom Palmer Eye Institute and later secured the intellectual property surrounding that finding. With an exclusive option agreement in hand, the Company has the necessary footing to make further investments in prosecuting MANF’s full potential in RP. Now midway through 2014, the Company is in the process of executing a methodical plan to deliver on the potential for MANF in RP, as well as continuing to expand with data the underlying scientific principles supporting MANF into new areas of research creating valuable intellectual property and know-how. Some of the key steps completed thus far include:
- The Company has received interim data and is awaiting final results for functional assessments for MANF from a leading contract research lab with specialty in RP rodent models;
- The Company has received interim data and is awaiting final results for toxicology safety assessments for MANF from a leading contract lab with specialty in rabbit ophthalmological models;
- Researchers at the University of Miami have completed running additional experiments for MANF in functional models of RP, and expect their findings to be published in peer-reviewed journals in the near future;
- The Company has received the final report from a leading contract research lab evaluating MANF’s activity in a tau hyperphosphorylation model of Alzheimer’s disease (AD). This study was conducted to confirm work previously published in a Chinese journal;
- The Company has identified a number of significant independent peer-reviewed research papers published in Chinese journals confirming previously published Western data, as well as identifying new uses for MANF;
- The Company has sourced contract manufacturing organizations capable of commercially manufacturing MANF, completed our due diligence and we expect to select a manufacturer in the third quarter.
All of the interim results we have seen to date in ophthalmology have been positive, which gives us a great deal of confidence heading into the second half of the year that RP will be the first of several INDs for MANF. All of the data being produced will be supportive of additional ophthalmological indications, including Wolfram’s-induced blindness which we are pursuing with Dr. Urano from the Washington University School of Medicine. Beyond these updates, the Company is establishing additional research collaborations with leading institutions in new and potentially groundbreaking areas, as well generating new IP surrounding the use of MANF in these various indications in the third quarter. We will be delivering the confirmatory AD results to the market very shortly, which in turn raises interesting prospects vis-a-vis our LymPro blood test for Alzheimer’s disease. When we first in-licensed LymPro, we had no idea that MANF could have an impact on aspects of the underlying pathophysiology of AD. However, with recently published data linking tau mis-folding to cell cycle dysregulation and amyloid aggregation, the prospect of MANF becoming the basis for new treatments in AD has become extremely interesting. Reproducibility is the hallmark of good science, and to date MANF has reproducibly demonstrated activity consistent with a breakthrough treatment across a highly valuable spectrum of indications. In addition, we are nearing the completion of the sourcing process necessary to retain our regulatory consulting group with expertise with a specialty in the area of ophthalmology to assist us in the filing of orphan drug designation with the FDA and EMA for MANF in RP. Based on the timelines and estimates we have received, we expect to submit to the FDA and receive a reply regarding our submission in the second half of this year, within the same time frame that we will be looking to up-list our common stock to a national exchange.
Last week we attended a successful BIO convention where we ended up participating in over 60 partnering meetings, and were extremely pleased with the reception we received from the community at large. It is clear that we have become highly visible to larger pharmaceutical companies, as well as promising early-stage companies seeking to partner their assets. The general theme was that each of our assets has tremendous promise within their own right, and most importantly that there is a strong scientific and business case to be made for each becoming a blockbuster asset. Taken together, the synergies created from a business perspective are able to insulate the Company from significant enterprise risk, and our ability to demonstrate progress with any of these assets will lend credibility to the rest of the portfolio. In light of these comments, we are now especially looking forward to the month of July which includes AAIC and our #C4CT Summit, as well as the rest of 2014. We believe the Company is growing stronger by the day and we are excited to share our enthusiasm with our fellow shareholders.
I thank you for taking the time to read this blog and look forward to updating you on additional progress for the Company as we achieve our true potential.
Warmest Regards,
Gerald E. Commissiong
President & CEO
- See more at: http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/manf-continues-deliver-heading-2h-14/#sthash.AWDxIeFt.dpuf
This is the best part:
That's right mate! NTEK is an easy 2-3 bagger from here.
Nuvolas are on their way!
Today may be the day!
Nothing like unexpected news to fire this rocket.
Would you also believe me if I tell you that NP-1s will be out pretty soon?
I'm also eager to see your review with pictures.
Did you try? I'm pretty sure he'll agree as soon as he knows you'll be performing the review. LOL.
Take care B402!
Not at all. It seems like you're dodging the request to provide your review. The reviews I'm talking about have been posted in this board.
In this forum we are willing to hear and accept/disagree with any perspective as long as it is well founded. At least I am.
The only way to debunk it is to go to conferences and NTEK's offices, which by the way, are not virtual offices; any one can walk in at any time, even unannounced.
Did you visit any of NTEK locations? You can even open one NP-1 and test it to support your assertion. Bring tech support, write a review, and share your conclusions with us.
I'm looking forward to it.
$NTEK
Making statements without properly seeing and getting answers from the people working on the device may be unwise.
Ohhh, I'm waiting for them to release the hounds.